



Longitudinal Analysis of the Effect of Maternal Immune Activation on Male Offspring Rhesus Monkeys in Human Intruder Test

Presenter: Min Kim
Graduate Group in Biostatistics, UC Davis



Topics

- Introduction
- Data
- Exploratory Analysis
- Modeling
- Results
- Conclusion



Introduction: Maternal Immune Activation Model

- Maternal immune activation (MIA) models of rodents and nonhuman primates have shown their powerful and translational utility to extended exploration of neurobiological mechanisms underlying human neurodevelopmental disorders (Kentner, 2019).
- MIA models use the viral mimic immunostimulant, Polyinosinic: polycytidylic acid stabilized with poly-L-lysine (Poly ICLC), to elicit an immune response during gestation.




Study: MIA model on Rhesus Monkeys

- Current ongoing study on 28 male offspring of rhesus monkeys from MIA-treated (Poly ICLC treated) (n = 14), saline (n = 10), or untreated (n = 4) dams.
- Human Intruder Test (HI Test) to assess the responsiveness of male offspring rhesus monkeys to the standardized conditions of a human intruder.

Human Intruder Test (HI Test)

- Human Intruder Test
 - 14 MIA-treated and 14 control male offspring rhesus monkey tested approximately at 1, 3, 6, 23, and 35 months of age
 - A session of 4 one-min trials of a human intruder's 4 conditions:
 - Each of the 4 conditions is scored as duration.





Study Question

- The scientific interest is to see whether there is a difference in “Front” duration under conditions: “Profile” and “Stare” between the group of male offspring rhesus monkeys of MIA-treated and control dams



Data: Human Intruder Positioning Data

- 36 total variables and attributes for 5 time points observations of 28 animals
Defining outcome:
 - Profile Front Duration: Average of Profile Far and Near
 - Stare Front Duration: Average of Stare Far and Near
- Predictors:
 - Actual age of animals at each time point
 - Treatment group (MIA vs. Control)
- Missing Data

Table 1. Subset Characteristics Summary of MIA and Control Group over 1 month to 35 months

	1 Month		3 Months		6 Months		23 Months		35 Months		Overall	
	MIA	Control	MIA	Control	MIA	Control	MIA	Control	MIA	Control	MIA	Control
	(N=14)	(N=12)	(N=13)	(N=14)	(N=14)	(N=14)	(N=13)	(N=14)	(N=13)	(N=14)	(N=67)	(N=68)
PF FRONT DUR (In Sec)												
Mean	24.1	37.9	39.3	38.0	28.0	35.8	36.3	35.4	33.9	36.4	32.1	36.7
(SD)	(18.2)	(25.6)	(17.2)	(11.9)	(18.5)	(19.3)	(15.3)	(17.5)	(14.9)	(18.0)	(17.3)	(18.2)
Median				38.8					36.1	37.3		
[Min, Max]	23.4 [0, 52.6]	49.2 [0, 60.0]	43.2 [0, 60.0]	[16.8, 60.0]	27.8 [0, 60.0]	35.6 [0, 60.0]	37.2 [0, 60.0]	39.4 [0, 53.9]	[8.76, 51.5]	[6.47, 60.0]	35.3 [0, 60.0]	38.8 [0, 60.0]
PN FRONT DUR (In Sec)												
Mean	23.7	43.6	41.3	31.3	31.4	25.9	34.7	33.6	30.2	28.5	32.1	32.3
(SD)	(21.7)	(22.9)	(19.4)	(13.4)	(16.4)	(18.7)	(17.9)	(13.5)	(12.2)	(15.5)	(18.3)	(17.5)
Median				35.0					34.6	29.3		
[Min, Max]	22.7 [0, 60.0]	54.5 [0, 60.0]	45.0 [0, 60.0]	[2.56, 47.5]	30.7 [0, 60.0]	29.6 [0, 49.4]	36.5 [0, 60.0]	37.2 [0, 57.5]	[6.30, 44.7]	[6.41, 55.7]	32.8 [0, 60.0]	37.1 [0, 60.0]
SF FRONT DUR (In Sec)												
Mean	29.0	34.5	47.8	40.5	45.3	37.4	34.7	29.5	26.0	24.4	36.6	33.2
(SD)	(24.4)	(22.5)	(12.7)	(18.6)	(10.9)	(18.4)	(9.24)	(12.6)	(11.6)	(14.0)	(16.9)	(17.8)
Median			53.2		44.4	42.4	38.7	26.4	29.9	21.6		
[Min, Max]	23.0 [0, 60.0]	38.6 [0, 60.0]	[26.8, 60.0]	43.5 [0, 60.0]	[30.1, 60.0]	[4.93, 60.0]	[16.0, 46.9]	[8.50, 54.1]	[5.53, 39.4]	[7.47, 54.1]	37.2 [0, 60.0]	34.5 [0, 60.0]
SN FRONT DUR (In Sec)												
Mean	20.1	42.7	41.1	31.1	39.3	34.2	29.1	23.9	28.8	28.6	31.6	31.8
(SD)	(19.2)	(22.9)	(16.8)	(17.3)	(14.9)	(19.1)	(9.96)	(13.5)	(14.0)	(15.7)	(16.8)	(18.3)
Median			41.1		38.3		31.7		27.1	30.6		
[Min, Max]	14.1 [0, 60.0]	58.7 [0, 60.0]	[9.47, 60.0]	30.1 [0, 60.0]	[14.2, 60.0]	40.4 [0, 58.8]	[9.97, 46.7]	26.8 [0, 46.6]	[8.94, 47.0]	[5.34, 60.0]	32.3 [0, 60.0]	31.3 [0, 60.0]
Abbreviations: MIA, Maternal Immune Activation, PF, Profile Far, PN, Profile Near, SF, Stare Far, SN, Stare Near												



Table 1. Subset Characteristics Summary of MIA and Control Group over 1 month to 35 months

	1 Month		3 Months		6 Months		23 Months		35 Months		Overall	
	MIA	Control	MIA	Control	MIA	Control	MIA	Control	MIA	Control	MIA	Control
	(N=14)	(N=12)	(N=13)	(N=14)	(N=14)	(N=14)	(N=13)	(N=14)	(N=13)	(N=14)	(N=67)	(N=68)
Accurate Age (In Days)												
Mean	30.1	30.3	91.3	90.5	180	179	705	695	1070	1060		
(SD)	(1.21)	(0.965)	(1.93)	(1.22)	(2.04)	(3.51)	(15.1)	(9.93)	(13.2)	(10.7)	406 (406)	423 (406)
Median	30.0	30.0	91.0	91.0					1070	1060		
[Min, Max]	[28.0, 32.0]	[29.0, 32.0]	[88.0, 94.0]	[88.0, 92.0]	180 [176, 184]	180 [171, 185]	706 [677, 725]	695 [678, 709]	[1040, 1090]	[1050, 1090]	180 [28.0, 1090]	180 [29.0, 1090]
Accurate Age (In Months)												
Mean	0.988	0.994	3.00	2.97	5.91	5.88	23.2	22.8	35.1	35.0	13.3	13.9
(SD)	(0.0396)	(0.0317)	(0.0635)	(0.0402)	(0.0670)	(0.115)	(0.498)	(0.326)	(0.433)	(0.351)	(13.3)	(13.3)
Median	0.986	0.986	2.99	2.99	5.91	5.91	23.2	22.8	35.1	34.8	5.91	5.91
[Min, Max]	[0.920, 1.05]	[0.953, 1.05]	[2.89, 3.09]	[2.89, 3.02]	[5.78, 6.05]	[5.62, 6.08]	[22.2, 23.8]	[22.3, 23.3]	[34.2, 35.7]	[34.5, 35.7]	[0.920, 35.7]	[0.953, 35.7]
Profile Front (PF + PN)/2												
Mean	23.9	40.8	40.3	34.7	29.7	30.8	35.5	34.5	32.1	32.5	32.1	34.5
(SD)	(18.8)	(22.8)	(17.6)	(9.44)	(16.3)	(16.2)	(15.6)	(13.8)	(12.3)	(14.3)	(16.8)	(15.5)
Median				36.0					37.9	35.0		
[Min, Max]	24.6 [0, 55.6]	51.8 [0, 60.0]	42.6 [0, 60.0]	[15.8, 46.2]	27.6 [0, 60.0]	32.8 [0, 50.0]	38.7 [0, 59.8]	36.8 [0, 55.7]	[7.53, 45.8]	[6.44, 57.8]	33.2 [0, 60.0]	36.6 [0, 60.0]
Stare Front (SF + SN)/2												
Mean	24.6	38.6	44.5	35.8	42.3	35.8	31.9	26.7	27.4	26.5	34.1	32.5
(SD)	(20.8)	(20.5)	(13.7)	(16.5)	(11.7)	(15.9)	(8.74)	(12.7)	(11.2)	(12.9)	(15.7)	(16.1)
Median			47.2		43.3	38.3	34.8	25.8	32.1	27.5		
[Min, Max]	18.9 [0, 60.0]	42.3 [0, 60.0]	[21.4, 60.0]	37.0 [0, 55.5]	[23.8, 60.0]	[2.47, 55.9]	[17.0, 42.7]	[4.25, 50.4]	[7.24, 39.5]	[6.90, 46.9]	34.6 [0, 60.0]	33.1 [0, 60.0]
Abbreviations: MIA, Maternal Immune Activation, PF, Profile Far, PN, Profile Near, SF, Stare Far, SN, Stare Near												

Outcome 1 →

Outcome 2 →

Exploratory Analysis





Method

- Modeling for outcome: Front duration in 2 conditions: Profile and Stare
 - Linear Mixed Effect Model
- Model Selection
- Assessment of Treatment Effect

Initial Model: Linear Mixed-Effect Model (ReML)

- $Y_{\{ij\}}$: front duration for subject i for either profile or stare
- $Age_{\{ij\}} - 1$: subject's age centered at 1 month, for $i = \{1, \dots, n_i\}$
- Time point $j = \{1, \dots, n_j\}$
- $Treatment_{\{i\}}$: indicator variable for $Treatment_{\{i\}} = 1$ for MIA, and $Treatment_{\{i\}} = 0$ for control group.

Consider the full model

$$Y_{\{ij\}} = \beta_0 + \beta_1 \{Treatment_{\{i\}}\} + \beta_2 \{Age_{\{ij\}} - 1\} + \beta_3 \{Age_{\{ij\}} - 1\}^2 + \beta_4 \{Age_{\{ij\}} - 1\}^3 \\ + \beta_5 \{Treatment_{\{i\}}\} * \{Age_{\{ij\}} - 1\} + \beta_6 \{Treatment_{\{i\}}\} * \{Age_{\{ij\}} - 1\}^2 \\ + \beta_7 \{Treatment_{\{i\}}\} * \{Age_{\{ij\}} - 1\}^3 + e_{\{ij\}},$$

$$e_{\{ij\}} = U_{0i} + Z_{ij}$$

with i.i.d. measurement error Z_{ij} , and U_{0i} is random intercept

$$Z_{ij} \sim N(0, \tau^2)$$

$$(U_{0i}) \sim N(0, G), E(U_{0i}) = (0), \text{Var}(U_{0i}) = G = (\sigma_{0i}^2).$$



Modeling: Profile Front Duration

Covariance Model for $\text{Var}(e_{\{ij\}})$

1. Exchangeable (Compound Symmetry) Covariance Model: $e_{\{ij\}} = U_{0i} + Z_{ij}$
2. Random Intercept + Random slope Model: $e_{\{ij\}} = U_{0i} + U_{1i}\{Age_{\{ij\}} - 1\} + Z_{ij}$

Covariance Model Comparison:

Model	BIC	AIC	Log Likelihood
1	1206.569	1178.127	-579.063
2	1216.258	1182.127	-579.063

Final Covariance Model: Exchangeable (Compound Symmetry) Covariance Model



Modeling Mean Model: Profile Front Duration

- Initial fitting of mean model with exchangeable covariance model
- Multiple testing for all interaction terms

Testing for multiple coefficients jointly:

$$H_0: \beta_5 = \beta_6 = \beta_7 = 0$$

H_a : At least one of $\beta_5, \beta_6, \beta_7$ is not equal to 0

- Sequentially test higher order “Age” effects while always keep treatment and linear age effect in the model (t-test)
- Decide on final model



Modeling Stare Front Duration

Covariance Model for $\text{Var}(e_{\{ij\}})$

1. Exchangeable (Compound Symmetry) Covariance Model: $e_{\{ij\}} = U_{0i} + Z_{ij}$
2. Random Intercept + Random slope Model: $e_{\{ij\}} = U_{0i} + U_{1i}\{Age_{\{ij\}} - 1\} + Z_{ij}$

Covariance Model Comparison:

Model	BIC	AIC	Log Likelihood
1	1186.714	1158.272	-569.136
2	1196.510	1162.380	-569.190

Final Covariance Model: Exchangeable (Compound Symmetry) Covariance Model



Modeling Mean Model: Stare Front Duration

- Initial fitting of mean model with exchangeable covariance model
- Multiple testing for all interaction terms

Testing for multiple coefficients jointly:

$$H_o: \beta_5 = \beta_6 = \beta_7 = 0$$

H_a: At least one of $\beta_5, \beta_6, \beta_7$ is not equal to 0

- Sequentially test higher order “Age” effects: while always keep treatment and linear age effect in the model (t-test)
- Decide on final model



Model Selection

- Both Profile and Stare Front duration:
 - All age interaction terms are not significant

Full Model vs. Model without all interaction terms	Profile Model	Stare Model
F-Statistic	1.319	1.860
P-value	0.272	0.073

- Profile: cubic, quadratic age are dropped by t-test
- Stare: cubic, quadratic age are not dropped by t-test



Results: Final Model

- Profile Front Duration

$$Y_{\{ij\}} = \beta_0 + \beta_1\{Treatment_{\{i\}}\} + \beta_2\{Age_{\{ij\}} - 1\} + U_{\{0i\}} + Z_{\{ij\}}$$

- Stare Front Duration

$$Y_{\{ij\}} = \beta_0 + \beta_1\{Treatment_{\{i\}}\} + \beta_2\{Age_{\{ij\}} - 1\} + \beta_3\{Age_{\{ij\}} - 1\}^2 + \beta_4\{Age_{\{ij\}} - 1\}^3 + U_{\{0i\}} + Z_{\{ij\}}$$

Results: Final Model

Table 2: Fixed-Effect Parameter Estimates (SE) for the linear mixed-effects models predicting Profile and Stare Front Duration

Model Term	<i>Dependent variable:</i>	
	Profile Front Duration	Stare Front Duration
	Estimate (SE) p-value	Estimate (SE) p-value
Intercept	34.585*** (2.393) p = 0.000	31.811*** (3.05) p = 0.000
Treatment: MIA vs. Control	-2.353 (2.793) p = 0.408	1.514 (2.633) p = 0.571
Linear Age	-0.008 (0.105) p = 0.937	2.559** (1.216) p = 0.038
Quadratic Age		-0.203** (0.086) p = 0.021
Cubic Age		0.004** (0.020) p = 0.024
Observations	135	135

*p<0.01 **p<0.05 ***p<0.01




Results: Final Model (continued)


- No interaction of treatment and age are significant (profile: $p = 0.2722758$, stare: $p = 0.0728028$)
 - Effect of treatment on front duration is not significantly different over time
 - Profile (est. = -2.353, $p = 0.408$), Stare (est. = 1.514, $p = 0.571$)
 - Effect of age on front duration is not significantly different across MIA and control group with linear age not significant for profile front duration (est. = -0.008, $p = 0.937$) and linear, quadratic, cubic age significant for stare front duration (est. = 2.559, $p = 0.038$, est = -0.203, = 0.021, est = 0.004, $p = 0.024$, respectively).

Model Diagnostics

Fitted Coefficient Mean Functions: Profile




Fitted Coefficient Mean Functions: Stare






Model Diagnostics: Conditional Residual Analysis

Profile




Stare




Model Diagnostics: Conditional Residual Analysis

Normal Q-Q Plot




Normal Q-Q Plot






Model Diagnostics: Random Intercept

Boxplot of Random Intercept (Profile)



Random Intercept

Boxplot of Random Intercept (stare)



Random Intercept



Conclusion

- Treatment effect is not different over time for profile and stare conditions.
- Age effect is not different across treatment group for profile and stare conditions.
- MIA and control group perform similarly on “Front” duration on human intruder’s conditions.
- Possible future investigation on other outcome measures of the HI test
 - Frequency of position change
 - Frequency of various types of behaviors



References

Bauman, M. D., A. M. Iosif, S. E. Smith, C. Bregere, D. G. Amaral and P. H. Patterson (2014). "Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring." *Biol Psychiatry* 75(4): 332-341.

Gottlieb DH, Capitanio JP. "Latent variables affecting behavioral response to the human intruder test in infant rhesus macaques (*Macaca mulatta*)." *Am J Primatol*. 2013 Apr;75(4):314-23. doi: 10.1002/ajp.22107. Epub 2012 Dec 10. PMID: 23229557; PMCID: PMC3581725.

Kentner AC, Bilbo SD, Brown AS, Hsiao EY, McAllister AK, Meyer U, Pearce BD, Pletnikov MV, Yolken RH, Bauman MD. "Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model." *Neuropsychopharmacology*. 2019 Jan;44(2):245-258. doi: 10.1038/s41386-018-0185-7. Epub 2018 Aug 21. PMID: 30188509; PMCID: PMC6300528.

Vlasova RM, Iosif AM, Ryan AM, Funk LH, Murai T, Chen S, Lesh TA, Rowland DJ, Bennett J, Hogrefe CE, Maddock RJ, Gandal MJ, Geschwind DH, Schumann CM, Van de Water J, McAllister AK, Carter CS, Styner MA, Amaral DG, Bauman MD. "Maternal Immune Activation during Pregnancy Alters Postnatal Brain Growth and Cognitive Development in Nonhuman Primate Offspring." *J Neurosci*. 2021 Dec 1;41(48):9971-9987. doi: 10.1523/JNEUROSCI.0378-21.2021. Epub 2021 Oct 4. PMID: 34607967; PMCID: PMC8638691.